Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Aditya Bardia(UCLA Health), Sara A. Hurvitz(University of Washington), Kevin Punie(KU Leuven), Sabela Recalde(Institut Català d'Oncologia), Mu‐Hung Tsai, Amelia Zelnak(Northside Hospital), Priyanka Sharma(Chandigarh University), Javier Cortés(Villa Maria Hospital), Lisa A. Carey(University of North Carolina at Chapel Hill), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), T Traina(Memorial Sloan Kettering Cancer Center), Kevin Kalinsky(Emory University), Véronique Dièras(Institut Curie), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Florence Dalenc(Institut Claudius Regaud), Loretta M. Itri(National Institutes of Health), Sagar Sardesai(The Ohio State University Wexner Medical Center), Sara M. Tolaney(Harvard University), Joyce O’Shaughnessy(Baylor University Medical Center), Eva Ciruelos Gil(Hospital Universitario 12 De Octubre), Philippe Aftimos(Institut Jules Bordet), Hope S. Rugo(City of Hope), Q. Hong(Immunomedics (United States)), Martin Olivo(Gilead Sciences (United States)), Erika Hamilton(Sarah Cannon), Delphine Loirat(Institut Curie), David M. Goldenberg(Unknown)
Cited by 294
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k